These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8823479)

  • 1. A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate.
    Pienta KJ; Redman BG; Esper PS; Flaherty LE
    Am J Clin Oncol; 1996 Oct; 19(5):500-3. PubMed ID: 8823479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
    Hudes GR; Nathan F; Khater C; Haas N; Cornfield M; Giantonio B; Greenberg R; Gomella L; Litwin S; Ross E; Roethke S; McAleer C
    J Clin Oncol; 1997 Sep; 15(9):3156-63. PubMed ID: 9294479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer.
    Colleoni M; Graiff C; Vicario G; Nelli P; Sgarbossa G; Pancheri F; Manente P
    Am J Clin Oncol; 1997 Aug; 20(4):383-6. PubMed ID: 9256895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.
    Carles J; Domenech M; Gelabert-Mas A; Nogue M; Tabernero JM; Arcusa A; Guasch I; Miguel A; Ballesteros JJ; Fabregat X
    Acta Oncol; 1998; 37(2):187-91. PubMed ID: 9636014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.
    Hudes G; Einhorn L; Ross E; Balsham A; Loehrer P; Ramsey H; Sprandio J; Entmacher M; Dugan W; Ansari R; Monaco F; Hanna M; Roth B
    J Clin Oncol; 1999 Oct; 17(10):3160-6. PubMed ID: 10506613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma.
    Feun LG; Savaraj N; Hurley J; Marini A; Lai S
    Cancer; 2000 Feb; 88(3):584-8. PubMed ID: 10649251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral estramustine and oral etoposide for hormone-refractory prostate cancer.
    Dimopoulos MA; Panopoulos C; Bamia C; Deliveliotis C; Alivizatos G; Pantazopoulos D; Constantinidis C; Kostakopoulos A; Kastriotis I; Zervas A; Aravantinos G; Dimopoulos C
    Urology; 1997 Nov; 50(5):754-8. PubMed ID: 9372887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer.
    Attivissimo LA; Fetten JV; Kreis W
    Am J Clin Oncol; 1996 Dec; 19(6):581-3. PubMed ID: 8931676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer.
    Hamilton M; Dahut W; Brawley O; Davis P; Wells-Jones T; Kohler D; Duray P; Liewehr DJ; Lakhani N; Steinberg SM; Figg WD; Reed E
    Acta Oncol; 2003; 42(3):195-201. PubMed ID: 12852695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ; Smith DC
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
    Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
    Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
    Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone.
    Akerley W; Butera J; Wehbe T; Noto R; Stein B; Safran H; Cummings F; Sambandam S; Maynard J; Di Rienzo G; Leone L
    Cancer; 2002 Mar; 94(6):1654-60. PubMed ID: 11920525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.
    Goodin S; Rao KV; Kane M; Dave N; Capanna T; Doyle-Lindrud S; Engle E; Jin L; Todd M; DiPaola RS
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):199-204. PubMed ID: 15838657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
    Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.
    Bergan RC; Reed E; Myers CE; Headlee D; Brawley O; Cho HK; Figg WD; Tompkins A; Linehan WM; Kohler D; Steinberg SM; Blagosklonny MV
    Clin Cancer Res; 1999 Sep; 5(9):2366-73. PubMed ID: 10499606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.
    Hudes GR; Greenberg R; Krigel RL; Fox S; Scher R; Litwin S; Watts P; Speicher L; Tew K; Comis R
    J Clin Oncol; 1992 Nov; 10(11):1754-61. PubMed ID: 1383436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
    Smith DC; Esper P; Strawderman M; Redman B; Pienta KJ
    J Clin Oncol; 1999 Jun; 17(6):1664-71. PubMed ID: 10561202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
    Pienta KJ; Redman B; Hussain M; Cummings G; Esper PS; Appel C; Flaherty LE
    J Clin Oncol; 1994 Oct; 12(10):2005-12. PubMed ID: 7523606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.